KYORIN Pharmaceutical Full Year 2024 Earnings: In Line With Expectations

KYORIN Pharmaceutical (TSE:4569) Full Year 2024 Results

Key Financial Results

• Revenue: JP¥119.5b (up 5.5% from FY 2023).
• Net income: JP¥5.32b (up 13% from FY 2023).
• Profit margin: 4.5% (up from 4.2% in FY 2023). The increase in margin was driven by higher revenue.
• EPS: JP¥92.74 (up from JP¥82.42 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

KYORIN Pharmaceutical Meets Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.

Looking ahead, revenue is expected to decline by 2.3% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 4.5%.

Performance of the Japanese Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with KYORIN Pharmaceutical.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.